drs. A.J. van der Wekken

pulmonary oncologist

E-mail:
a.j.van.der.wekken umcg.nl

Research

Publications
  1. Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

    Gijtenbeek, R. G. P., de Jong, K., Venmans, B. J. W., van Vollenhoven, F. H. M., Brinke, A. T., Van der Wekken, A. J. & van Geffen, W. H., 12-Aug-2019, In : Cochrane Database of Systematic Reviews. 2019, 8, CD013382.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

    van Veggel, B., Madeira R Santos, J. F. V., Hashemi, S. M. S., Paats, M. S., Monkhorst, K., Heideman, D. A. M., Groves, M., Radonic, T., Smit, E. F., Schuuring, E., van der Wekken, A. J. & de Langen, A. J., Mar-2020, In : Lung Cancer. 141, p. 9-13 5 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Detecting therapy-guiding aberrations in platelets and plasma at the transcriptome level in non-small-cell lung cancer

    Meng, P., Rybczynska, A. A., Wei, J., Terpstra, M. M., Timens, W., Schuuring, E., Hiltermann, T. J. N., Groen, H. J. M., Kok, K., Van der Wekken, A. J. & Van den Berg, A., Nov-2019, In : Annals of Oncology. 30, 1 p., UNSP mdz413.025.

    Research output: Contribution to journalMeeting AbstractAcademic

View all (42) »

Press / Media
  1. Plasma testing

    Anthonie Wekken, van der

    15/11/2019

    1 Media contribution

    Press/Media: Expert CommentAcademic

  2. Longkanker in Perspectief

    Anthonie Wekken, van der

    05/11/2019

    1 Media contribution

    Press/Media: Expert CommentProfessional

  3. Magazine Longkanker

    Anthonie Wekken, van der

    15/05/2019

    1 Media contribution

    Press/Media: Public Engagement ActivitiesProfessional

View all (6) »

Activities
  1. ALK treatment and resistance in NSCLC

    Anthonie Wekken, van der (Speaker)
    5-Feb-2020

    Activity: Talk or presentationAcademic

  2. ALK treatment and resistance in NSCLC

    Anthonie Wekken, van der (Speaker)
    4-Feb-2020

    Activity: Talk or presentationAcademic

  3. Treatment of mutations with TKI

    Anthonie Wekken, van der (Speaker)
    2-May-2019

    Activity: Talk or presentationProfessional

View all (12) »

ID: 35892471